Abstract
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antifungal Agents / adverse effects*
-
Antifungal Agents / therapeutic use
-
Caspofungin
-
Child
-
Child, Preschool
-
Clinical Trials as Topic
-
Echinocandins / adverse effects*
-
Echinocandins / therapeutic use
-
Humans
-
Infant
-
Infant, Newborn
-
Lipopeptides
-
Mycoses / drug therapy*
-
Prospective Studies
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Caspofungin